Glaucoma treatment increases graft failure risk

Article

Escalating treatment for glaucoma patients who have undergone penetrating keratoplasty (PK) significantly increases the risk of graft failure and poor visual outcomes.

Escalating treatment for glaucoma patients who have undergone penetrating keratoplasty (PK) significantly increases the risk of graft failure and poor visual outcomes, according to a report published in the December 2007 issue of Ophthalmology.

Mansour Al-Mohaimeed, MD and colleagues from the King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia and the University of Iowa Hospitals and Clinics, Iowa City, USA reviewed the data for 715 eyes of 678 patients who had undergone PK at the King Khaled Eye Specialist Hospital over a two-year period. The prevalence and risk factors of escalation of glaucoma therapy and the effects on graft survival were evaluated.

Over a mean follow-up period of 32.2 months, treatment for glaucoma escalated in 89 eyes (12.4%). Medical escalation accounted for 73 (82%) cases and surgical escalation occurred in 16 (15%) eyes. The surgical indication for PK (p<0.001), increasing patient age (p<0.001), pre-existing glaucoma (p<0.001), recipient trephination (p=0.02) and being either pseudophakic or aphakic (p<0.001) were all significantly associated with an increased risk of glaucoma therapy escalation.

Eyes in which glaucoma therapy did escalate also had a significant reduction in graft survival, with 52.8% of grafts surviving among these eyes compared with 82.9% of eyes with treatment escalation. Furthermore, increased treatment for glaucoma significantly affected final visual acuity (VA). Just 9% of eyes in the escalated treatment group achieved a VA of 20/40 or better compared with 42.1% of eyes that did not require an increase in treatment.

The results of this study suggest that escalating treatment for glaucoma patients who have undergone PK, can significantly increase the risk of poor visual outcomes and graft failure.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.